AJP - Heart AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 270: H53-H64, 1996;
0363-6135/96 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perez, R. G.
Right arrow Articles by Becker, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perez, R. G.
Right arrow Articles by Becker, L. C.

AJP - Heart and Circulatory Physiology, Vol 270, Issue 1 53-H64, Copyright © 1996 by American Physiological Society


ARTICLES

Factors modifying protective effect of anti-CD18 antibodies on myocardial reperfusion injury in dogs

R. G. Perez, M. Arai, C. Richardson, A. DiPaula, C. Siu, N. Matsumoto, J. E. Hildreth, M. M. Mariscalco, C. W. Smith and L. C. Becker
Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.

Anti-CD18 monoclonal antibodies (MAb) have demonstrated variable protection against neutrophil (PMN)-mediated myocardial reperfusion injury. To identify factors contributing to this variability, open-chest dogs underwent coronary artery occlusion for 90 min followed by reperfusion for 3.5 h. Ten minutes before reperfusion the dogs received saline (n = 18) or one of three anti-CD18 MAb: MHM.23, R15.7, or PLM-2 (2, 1, and 1 mg/kg and n = 19, 8, and 4, respectively). Collateral flow was measured with radioactive microspheres, area at risk was assessed with monastral blue dye, and infarct size was measured postmortem by triphenyltetrazolium chloride. In vitro, all three MAb bound to canine PMNs, but only MHM.23 and R15.7 inhibited their adherence to keyhole limpet hemocyanin-coated plastic. In vivo, only MHM.23 and R15.7 significantly reduced infarct size after adjusting for the effect of collateral flow. MHM.23 afforded protection in dogs with moderate ischemia (epicardial collateral flow > 0.1 ml.min-1.g-1, infarct size reduced 46%) but not in dogs with more severe ischemia. Only R15.7 was effective in dogs with severe ischemia. Although MHM.23 and R15.7 produced similar inhibition of tissue PMN accumulation, as reflected by myeloperoxidase activity. R15.7 markedly inhibited H2O2 production by PMNs after exposure to platelet-activating factor, whereas MHM.23 had only a minimal effect. The effectiveness of different anti-CD18 MAb in preventing reperfusion injury appears to be 1) highly dependent on the specific anti-CD18 MAb employed, 2) predicted only partially by in vitro binding to PMNs, static in vitro tests of PMN adherence, or the extent of inhibition of PMN accumulation in vivo, 3) related more to their ability to inhibit oxidant release from activated PMNs, and 4) strongly influenced by the severity of myocardial ischemia before reperfusion.


This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
E. O. Weinberg, M. Scherrer-Crosbie, M. H. Picard, B. A. Nasseri, C. MacGillivray, J. Gannon, Q. Lian, K. D. Bloch, and R. T. Lee
Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion
Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1802 - H1809.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Vinten-Johansen
Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury
Cardiovasc Res, February 15, 2004; 61(3): 481 - 497.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. H. Merchant, D. M. Gurule, and R. S. Larson
Amelioration of ischemia-reperfusion injury with cyclic peptide blockade of ICAM-1
Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1260 - H1268.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. W. Baran, M. Nguyen, G. R. McKendall, C. T. Lambrew, G. Dykstra, S. T. Palmeri, R. J. Gibbons, S. Borzak, B. E. Sobel, S. G. Gourlay, et al.
Double-Blind, Randomized Trial of an Anti-CD18 Antibody in Conjunction With Recombinant Tissue Plasminogen Activator for Acute Myocardial Infarction: Limitation of Myocardial Infarction Following Thrombolysis in Acute Myocardial Infarction (LIMIT AMI) Study
Circulation, December 4, 2001; 104(23): 2778 - 2783.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. A. Briaud, Z.-M. Ding, L. H. Michael, M. L. Entman, S. Daniel, and C. M. Ballantyne
Leukocyte trafficking and myocardial reperfusion injury in ICAM-1/P-selectin-knockout mice
Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H60 - H67.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. C. Becker, R. W. Jeremy, J. Schaper, and W. Schaper
Ultrastructural assessment of myocardial necrosis occurring during ischemia and 3-h reperfusion in the dog
Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H243 - H252.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. J. Palazzo, S. P. Jones, W. G. Girod, D. C. Anderson, D. N. Granger, and D. J. Lefer
Myocardial ischemia-reperfusion injury in CD18- and ICAM-1-deficient mice
Am J Physiol Heart Circ Physiol, December 1, 1998; 275(6): H2300 - H2307.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online